ImmuCell reports record Q1 2025 sales of $8.1M, up 11% YoY

IMMUCELL CORP /DE/

2025-Q1 EPS reported $0.16 revenue$8,067,174

Preliminary unaudited product sales for Q1 2025: $8.1M, up 11% from $7.3M in Q1 2024.
All-time quarterly sales record; six-month ($15.8M) and twelve-month ($27.3M) periods also record.
Order backlog reduced to $4.0M as of March 31, 2025, from $4.4M at Dec 31, 2024.
Annualized Q1 sales were approximately 108% of estimated $30M annual capacity.
NADA submission for Re-Tain progressing; critical path remains inspection at contract manufacturer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.